HRP20240182T1 - Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2) - Google Patents
Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2) Download PDFInfo
- Publication number
- HRP20240182T1 HRP20240182T1 HRP20240182TT HRP20240182T HRP20240182T1 HR P20240182 T1 HRP20240182 T1 HR P20240182T1 HR P20240182T T HRP20240182T T HR P20240182TT HR P20240182 T HRP20240182 T HR P20240182T HR P20240182 T1 HRP20240182 T1 HR P20240182T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- amino acid
- acid sequence
- seq
- antibody fragment
- Prior art date
Links
- 241001678559 COVID-19 virus Species 0.000 title claims 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 50
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims 36
- 230000035772 mutation Effects 0.000 claims 5
- 229940096437 Protein S Drugs 0.000 claims 4
- 101710198474 Spike protein Proteins 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 1
- 230000001010 compromised effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Claims (22)
1. Protutijelo ili fragment protutijela koji se veže na površinski šiljasti protein SARS-CoV-2, naznačeno time što protutijelo ili fragment protutijela sadrži CDRH1 koja sadrži aminokiselinsku sekvencu SEQ ID NO:59, CDRH2 koja sadrži aminokiselinsku sekvencu SEQ ID NO:60, CDRH3 koja sadrži aminokiselinsku sekvencu SEQ ID NO:61, CDRL1 koja sadrži aminokiselinsku sekvencu SEQ ID NO:89, CDRL2 koja sadrži aminokiselinsku sekvencu SEQ ID NO:90, CDRL3 koji sadrži aminokiselinska sekvenca SEQ ID NO:91.
2. Protutijelo ili fragment protutijela prema zahtjevu 1, naznačeno time što protutijelo ili fragment protutijela sadrži varijabilne sekvence teškog i lakog lanca koje imaju najmanje 70%, 80%, 90% ili 95% identičnosti sa aminokiselinskom sekvencom SEQ ID NO: 33 i aminokiselinskom sekvencom SEQ ID NO:34.
3. Protutijelo ili fragment protutijela prema zahtjevu 1, naznačeno time što protutijelo ili fragment protutijela sadrži varijabilnu sekvencu teškog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 33 i varijabilnu sekvencu lakog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 34.
4. Protutijelo ili fragment protutijela koji se veže na površinski šiljasti protein SARS-CoV-2, naznačeno time što protutijelo ili fragment protutijela sadrži CDRH1 koja sadrži aminokiselinsku sekvencu SEQ ID NO:68, CDRH2 koja sadrži aminokiselinsku sekvencu SEQ ID NO:69, CDRH3 koja sadrži aminokiselinsku sekvencu SEQ ID NO:70, CDRL1 koja sadrži aminokiselinsku sekvencu SEQ ID NO:98, CDRL2 koja sadrži aminokiselinsku sekvencu SEQ ID NO:99, CDRL3 koja sadrži aminokiselinska sekvenca SEQ ID NO:100.
5. Protutijelo ili fragment protutijela prema zahtjevu 4, naznačeno time što protutijelo ili fragment protutijela sadrži varijabilne sekvence teškog i lakog lanca koje imaju najmanje 70%, 80%, 90% ili 95% identičnosti sa aminokiselinskom sekvencom SEQ ID NO: 39 i aminokiselinskom sekvencom SEQ ID NO:40.
6. Protutijelo ili fragment protutijela prema zahtjevu 4, naznačeno time što protutijelo ili fragment protutijela sadrži varijabilnu sekvencu teškog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 39 i varijabilnu sekvencu lakog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 40.
7. Protutijelo ili fragment protutijela prema bilo kojem od zahtjeva 1-6, naznačeno time što protutijelo ili fragment protutijela sadrži YTE mutaciju.
8. Protutijelo ili fragment protutijela prema bilo kojem od zahtjeva 1-7, naznačeno time što je protutijelo ili fragment protutijela IgG protutijelo ili fragment.
9. Protutijelo ili fragment protutijela prema zahtjevu 8, naznačeno time što je IgG protutijelo ili fragment IgG1 protutijelo.
10. Farmaceutski prihvatljiv pripravak, naznačen time što sadrži protutijelo ili fragment protutijela prema bilo kojem od zahtjeva 1-9, izborno pri čemu je pripravak formuliran za intravensku primjenu.
11. Farmaceutski prihvatljiv pripravak koja sadrži prvo protutijelo ili fragment protutijela koji je protutijelo ili fragment protutijela prema bilo kojem od zahtjeva 1-3 i drugo protutijelo ili fragment protutijela koji je protutijelo ili fragment protutijela prema bilo kojem od zahtjeva 4- 6.
12. Farmaceutski prihvatljiv pripravak prema zahtjevu 11, naznačen time što prvo protutijelo ili fragment protutijela sadrži YTE mutaciju, a drugo protutijelo ili fragment protutijela sadrži YTE mutaciju.
13. Farmaceutski prihvatljiv pripravak prema zahtjevu 11 ili 12, naznačen time što je prvo protutijelo ili fragment protutijela IgG1 protutijelo, a drugo protutijelo ili fragment protutijela je IgG1 protutijelo.
14. Kombinacija prvog protutijela ili fragmenta protutijela koji se veže na površinski šiljasti protein SARS-CoV-2 i drugog protutijela ili fragmenta protutijela koji se veže na površinski šiljasti protein SARS-CoV-2 za upotrebu u postupku za liječenje ili sprječavanje infekcije SARS-CoV-2 kod subjekta, naznačena time što
prvo protutijelo ili fragment protutijela sadrži CDRH1 koja sadrži aminokiselinsku sekvencu SEQ ID NO:59, CDRH2 koja sadrži aminokiselinsku sekvencu SEQ ID NO:60, CDRH3 koja sadrži aminokiselinsku sekvencu SEQ ID NO:61, CDRL1 koja sadrži aminokiselinsku sekvencu SEQ ID NO:89, CDRL2 koja sadrži aminokiselinsku sekvencu SEQ ID NO:90, CDRL3 koja sadrži aminokiselinsku sekvencu SEQ ID NO:91; i
drugo protutijelo ili fragment protutijela sadrži CDRH1 koja sadrži aminokiselinsku sekvencu SEQ ID NO:68, CDRH2 koja sadrži aminokiselinsku sekvencu SEQ ID NO:69, CDRH3 koja sadrži aminokiselinsku sekvencu SEQ ID NO:70, CDRL1 koja sadrži aminokiselinsku sekvencu SEQ ID NO: 98, CDRL2 koja sadrži aminokiselinsku sekvencu SEQ ID NO: 99, CDRL3 koja sadrži aminokiselinsku sekvencu SEQ ID NO: 100.
15. Kombinacija za upotrebu prema zahtjevu 14, naznačena time što prvo protutijelo ili fragment protutijela sadrži varijabilnu sekvencu teškog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO:33 i varijabilnu sekvencu lakog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: :34.
16. Kombinacija za upotrebu prema zahtjevu 14 ili 15, naznačena time što drugo protutijelo ili fragment protutijela sadrži varijabilnu sekvencu teškog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO:39 i varijabilnu sekvencu lakog lanca koja sadrži aminokiselinsku sekvencu SEQ. ID NO:40.
17. Kombinacija za upotrebu prema bilo kojem od zahtjeva 14-16, naznačena time što prvo protutijelo ili fragment protutijela sadrži YTE mutaciju, a drugo protutijelo ili fragment protutijela sadrži YTE mutaciju.
18. Kombinacija za upotrebu prema bilo kojem od zahtjeva 14-17, naznačena time što je prvo protutijelo ili fragment protutijela IgG protutijelo ili fragment, a drugo protutijelo ili fragment protutijela je IgG protutijelo ili fragment.
19. Kombinacija za upotrebu prema bilo kojem od zahtjeva 14-18, naznačena time što je prvo protutijelo ili fragment protutijela IgG1 protutijelo; a drugo protutijelo ili fragment protutijela je IgG1 protutijelo.
20. Kombinacija za upotrebu prema bilo kojem od zahtjeva 14-19, naznačena time što je prvo protutijelo ili fragment protutijela formuliran za intravensku primjenu i/ili drugo protutijelo ili fragment protutijela je formuliran za intravensku primjenu.
21. Kombinacija za upotrebu prema bilo kojem od zahtjeva 14-20, naznačena time što su prvo protutijelo ili fragment protutijela i drugo protutijelo ili fragment protutijela u istom farmaceutski prihvatljivom pripravku.
22. Kombinacija za upotrebu prema bilo kojem od zahtjeva 14-21, naznačena time što subjekt:
(i) ima 60 ili više godina,
(ii) je imunološki kompromitiran, ili
(iii) pati od respiratornog i/ili kardiovaskularnog poremećaja.
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000299P | 2020-03-26 | 2020-03-26 | |
| US202063002896P | 2020-03-31 | 2020-03-31 | |
| US202063003716P | 2020-04-01 | 2020-04-01 | |
| US202063023545P | 2020-05-12 | 2020-05-12 | |
| US202063024248P | 2020-05-13 | 2020-05-13 | |
| US202063024204P | 2020-05-13 | 2020-05-13 | |
| US202063027173P | 2020-05-19 | 2020-05-19 | |
| US202063037984P | 2020-06-11 | 2020-06-11 | |
| US202063040246P | 2020-06-17 | 2020-06-17 | |
| US202063040224P | 2020-06-17 | 2020-06-17 | |
| US202163142196P | 2021-01-27 | 2021-01-27 | |
| US202163161890P | 2021-03-16 | 2021-03-16 | |
| PCT/US2021/024215 WO2021195418A1 (en) | 2020-03-26 | 2021-03-25 | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
| EP21719462.0A EP4045533B1 (en) | 2020-03-26 | 2021-03-25 | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240182T1 true HRP20240182T1 (hr) | 2024-04-26 |
Family
ID=75540042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240182TT HRP20240182T1 (hr) | 2020-03-26 | 2021-03-25 | Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2) |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US11345741B2 (hr) |
| EP (2) | EP4356924A3 (hr) |
| JP (1) | JP2023518849A (hr) |
| KR (1) | KR20220158053A (hr) |
| CN (1) | CN115768790A (hr) |
| AU (1) | AU2021242306A1 (hr) |
| BR (1) | BR112022018949A2 (hr) |
| CA (1) | CA3175110A1 (hr) |
| CL (1) | CL2022002594A1 (hr) |
| CO (1) | CO2022014820A2 (hr) |
| CR (1) | CR20220545A (hr) |
| DK (1) | DK4045533T5 (hr) |
| DO (1) | DOP2022000199A (hr) |
| EC (1) | ECSP22083269A (hr) |
| ES (1) | ES2973425T3 (hr) |
| FI (1) | FI4045533T3 (hr) |
| HR (1) | HRP20240182T1 (hr) |
| HU (1) | HUE065039T2 (hr) |
| IL (1) | IL296537A (hr) |
| LT (1) | LT4045533T (hr) |
| MX (1) | MX2022011892A (hr) |
| PE (1) | PE20230415A1 (hr) |
| PH (1) | PH12022552500A1 (hr) |
| PL (1) | PL4045533T3 (hr) |
| PT (1) | PT4045533T (hr) |
| RS (1) | RS65199B1 (hr) |
| SI (1) | SI4045533T1 (hr) |
| SM (1) | SMT202400070T1 (hr) |
| TW (1) | TW202200610A (hr) |
| UY (1) | UY39135A (hr) |
| WO (1) | WO2021195418A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021242306A1 (en) | 2020-03-26 | 2022-11-17 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| KR20230016184A (ko) | 2020-04-27 | 2023-02-01 | 트위스트 바이오사이언스 코포레이션 | 코로나바이러스에 대한 변이체 핵산 라이브러리 |
| WO2022020234A2 (en) * | 2020-07-20 | 2022-01-27 | Bio-Rad Laboratories, Inc. | Immunoassay for sars-cov-2 neutralizing antibodies and materials therefor |
| BR112023002234A2 (pt) * | 2020-08-10 | 2023-03-07 | Astrazeneca Uk Ltd | Anticorpos sars-cov-2 para tratamento e prevenção de covid-19 |
| US12169200B2 (en) | 2020-08-11 | 2024-12-17 | Zoetis Services Llc | Lateral flow device for detecting SARS-CoV-2 antibodies in human and animal samples |
| US11440952B2 (en) | 2020-10-16 | 2022-09-13 | Invisishield Technologies Ltd. | Compositions for preventing or treating viral and other microbial infections |
| TW202342095A (zh) * | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | 用於治療和預防ｃｏｖｉｄ—１９之組成物 |
| WO2023108936A1 (zh) * | 2021-12-14 | 2023-06-22 | 杭州安旭生物科技股份有限公司 | 一种可结合SARS-CoV-2病毒的中和抗体及其应用 |
| TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Ｒｑ生物科技有限公司 | 抗體 |
| AU2023262192A1 (en) * | 2022-04-29 | 2024-12-05 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
| CN114870061B (zh) * | 2022-05-31 | 2024-09-24 | 康码（上海）生物科技有限公司 | 一种基于病毒阻断剂的空气喷雾剂及其用途 |
| WO2024019110A1 (ja) * | 2022-07-20 | 2024-01-25 | 国立感染症研究所長が代表する日本国 | ＳＡＲＳ－ＣｏＶ－２に対する抗体 |
| CN115925934A (zh) * | 2022-07-26 | 2023-04-07 | 北京昌平实验室 | 一种稳定性提高的人源化单克隆抗体及其应用 |
Family Cites Families (194)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4122427A (en) | 1976-06-24 | 1978-10-24 | Herbert Karsh | Motion monitor |
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| JPS58188433A (ja) | 1982-04-28 | 1983-11-02 | アロカ株式会社 | 超音波診断装置 |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5141648A (en) | 1987-12-02 | 1992-08-25 | Neorx Corporation | Methods for isolating compounds using cleavable linker bound matrices |
| US5563250A (en) | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
| AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
| EP1026240A3 (en) | 1988-09-02 | 2004-04-07 | Dyax Corp. | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5088498A (en) | 1988-10-17 | 1992-02-18 | The Board Of Regents Of The University Of Washington | Ultrasonic plethysmograph |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| JPH03151944A (ja) | 1989-11-08 | 1991-06-28 | Hitachi Medical Corp | パルスドプラ計測装置 |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| JPH049249A (ja) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | 塗型剤吹き付け機 |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| EP0580737B1 (en) | 1991-04-10 | 2004-06-16 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| JPH0767451B2 (ja) | 1991-12-24 | 1995-07-26 | アロカ株式会社 | 超音波組織変位計測装置 |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5638824A (en) | 1993-02-25 | 1997-06-17 | Advanced Monitors Holdings Limited | Ultrasonic monitor |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| ES2201097T3 (es) | 1994-01-31 | 2004-03-16 | Trustees Of Boston University | Bibliotecas de anticuerpos policlonales. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5573012A (en) | 1994-08-09 | 1996-11-12 | The Regents Of The University Of California | Body monitoring and imaging apparatus and method |
| AU4289496A (en) | 1994-12-02 | 1996-06-19 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| DE19914455B4 (de) | 1999-03-30 | 2005-07-14 | Siemens Ag | Verfahren zur Bestimmung der Bewegung eines Organs oder Therapiegebiets eines Patienten sowie hierfür geeignetes System |
| EP1914244B1 (en) | 1999-04-09 | 2013-05-29 | Kyowa Hakko Kirin Co., Ltd. | Method of modulating the activity of functional immune molecules |
| US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
| ATE440959T1 (de) | 2000-06-28 | 2009-09-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
| EP1333032A4 (en) | 2000-10-06 | 2005-03-16 | Kyowa Hakko Kogyo Kk | METHOD FOR PURIFYING ANTIBODIES |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EA013224B1 (ru) | 2000-10-06 | 2010-04-30 | Киова Хакко Кирин Ко., Лтд. | Клетки, продуцирующие композиции антител |
| EP1208796B1 (de) | 2000-11-22 | 2003-03-05 | BrainLAB AG | Verfahren zur Bestimmung der Lungenfüllung |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| AU2002248184C1 (en) | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| EP1383800A4 (en) | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII |
| SE520605C2 (sv) | 2001-06-29 | 2003-07-29 | Flir Systems Ab | Optiskt system innefattande en detektor och en bländare med decentreringsfunktion |
| EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
| KR20040054669A (ko) | 2001-08-03 | 2004-06-25 | 글리카트 바이오테크놀로지 아게 | 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체 |
| US7601891B2 (en) | 2002-03-19 | 2009-10-13 | Plant Research International B.V. | Optimizing glycan processing plants |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US8814793B2 (en) | 2002-12-03 | 2014-08-26 | Neorad As | Respiration monitor |
| GB2396012B (en) | 2002-12-03 | 2006-03-15 | Neorad As | Respiration monitor |
| EP2264151B1 (en) | 2003-01-22 | 2016-04-20 | Roche Glycart AG | Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |
| US6932769B2 (en) | 2003-05-28 | 2005-08-23 | Delphi Technologies, Inc. | Ultrasonic occupant detection and classification system |
| AR047692A1 (es) | 2003-07-10 | 2006-02-08 | Epix Medical Inc | Imagenes de blancos estacionarios |
| US7750123B2 (en) | 2003-11-25 | 2010-07-06 | Dana Farber Cancer Institute, Inc. | Antibodies against SARS-CoV and methods of use thereof |
| CA2549188A1 (fr) | 2003-12-02 | 2005-06-23 | Universite Paris 7 | Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras |
| JP5529378B2 (ja) | 2004-08-31 | 2014-06-25 | ユニヴァーシティ オブ ワシントン | 狭窄血管における壁振動を評価するための超音波技法 |
| US20080146911A1 (en) | 2004-10-18 | 2008-06-19 | Kabushiki Kaisha Toshiba | Respiration Monitoring Apparatus, Respiration Monitoring System, Medical Processing System, Respiration Monitoring Method, And Respiration Monitoring Program |
| WO2006057911A2 (en) | 2004-11-22 | 2006-06-01 | Civco Medical Instruments Co., Inc. | Real time ultrasound monitoring of the motion of internal structures during respiration for control of therapy delivery |
| EP1874824A4 (en) | 2005-04-06 | 2009-12-30 | Ibc Pharmaceuticals Inc | METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF |
| MX2007013924A (es) | 2005-05-09 | 2008-01-28 | Glycart Biotechnology Ag | Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc. |
| US20060285071A1 (en) | 2005-06-21 | 2006-12-21 | Bausch & Lomb Incorporated | Femtosecond laser micromachining of a contact lens and a contact lens manufactured thereby |
| JPWO2007032329A1 (ja) | 2005-09-14 | 2009-03-19 | パナソニック株式会社 | 位置追跡方法、位置追跡装置および超音波診断装置 |
| CA2637254A1 (en) | 2006-01-17 | 2007-07-26 | Biolex Therapeutics, Inc. | Compositions and methods for humanization and optimization of n-glycans in plants |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| ATE468814T1 (de) | 2006-09-29 | 2010-06-15 | Koninkl Philips Electronics Nv | Verfahren und vorrichtung für freihändigen ultraschall |
| US20090048518A1 (en) | 2006-12-10 | 2009-02-19 | Cardio Art Technologies Ltd. | Doppler motion sensor apparatus and method of using same |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| CA2693677C (en) | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| CN101855242B (zh) | 2007-09-14 | 2014-07-30 | 阿迪马布有限责任公司 | 合理设计的合成抗体文库及其用途 |
| US10398393B2 (en) | 2007-10-02 | 2019-09-03 | Stryker European Holdings I, Llc | Dynamic reference method and system for interventional procedures |
| WO2014152463A1 (en) | 2013-03-15 | 2014-09-25 | Cyberheart, Inc. | Apparatus and method for real-time tracking of tissue structures |
| US20110159001A1 (en) * | 2008-01-17 | 2011-06-30 | Institute For Research In Biomedicine | CROSS-NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES TO SARS-CoV AND METHODS OF USE THEREOF |
| US20110257522A1 (en) | 2008-11-06 | 2011-10-20 | Neorad As | Injection of Fluid |
| WO2010059543A1 (en) | 2008-11-20 | 2010-05-27 | Merck Sharp & Dohme Corp. | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
| CN102307594A (zh) | 2009-01-06 | 2012-01-04 | 戴埃克斯有限公司 | 用激肽释放酶抑制剂治疗粘膜炎 |
| SG172354A1 (en) | 2009-01-29 | 2011-07-28 | Medimmune Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| US10098572B2 (en) | 2009-07-20 | 2018-10-16 | Koninklijke Philips N.V. | Method for operating a monitoring system |
| US20110121996A1 (en) | 2009-11-23 | 2011-05-26 | Delphi Technologies, Inc. | Method and System for Detecting an Occupant Using Reflected Signals |
| SMT202000195T1 (it) | 2009-11-24 | 2020-05-08 | Medimmune Ltd | Agenti leganti direzionati contro b7-h1 |
| US20110208060A1 (en) | 2010-02-24 | 2011-08-25 | Haase Wayne C | Non-contact Biometric Monitor |
| JP5492606B2 (ja) | 2010-03-03 | 2014-05-14 | アズビル株式会社 | 演算装置、及び演算装置を備えた流量計 |
| GB2479930B (en) | 2010-04-29 | 2017-12-06 | Respinor As | Coupling an ultrasound probe to the skin |
| BR112012027828A2 (pt) | 2010-05-03 | 2016-08-09 | Genentech Inc | composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína |
| KR102318383B1 (ko) | 2010-07-16 | 2021-10-27 | 아디맵 엘엘씨 | 항체 라이브러리 |
| ES2660013T3 (es) | 2010-08-13 | 2018-03-20 | Respiratory Motion, Inc. | Dispositivos y métodos para la monitorización de la variación respiratoria mediante la medición de volúmenes respiratorios, movimiento y variabilidad |
| EP2614084A4 (en) | 2010-09-09 | 2014-02-19 | Purdue Research Foundation | HUMANE FOLAT RECEPTOR BETA ANTIBODIES AND METHOD FOR THEIR USE |
| DK2691417T4 (en) | 2011-03-29 | 2025-01-02 | Roche Glycart Ag | Antistof fc-varianter |
| US9526476B2 (en) | 2011-04-12 | 2016-12-27 | Brigham And Women's Hospital, Inc. | System and method for motion tracking using unique ultrasound echo signatures |
| US20130030285A1 (en) | 2011-07-26 | 2013-01-31 | General Electric Company | System and method for integrating multiple data sources into an x-ray image referential |
| WO2013026092A1 (en) | 2011-08-22 | 2013-02-28 | Resmed Limited | Ultrasonic welding of fabrics for sleep apnea treatment |
| JP5950517B2 (ja) | 2011-09-02 | 2016-07-13 | キヤノン株式会社 | 被検体情報取得装置、被検体情報取得方法、及びプログラム |
| EP2822968B1 (en) | 2012-03-08 | 2018-01-10 | Janssen Vaccines & Prevention B.V. | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
| JP6391564B2 (ja) | 2012-04-30 | 2018-09-19 | メディミューン，エルエルシー | 低減されたエフェクター機能及び延長された半減期を有する分子、組成物、並びにそれらの使用 |
| ES2777778T3 (es) | 2012-05-11 | 2020-08-06 | Medimmune Ltd | Variantes de CTLA-4 |
| JP6096459B2 (ja) | 2012-10-04 | 2017-03-15 | 東芝メディカルシステムズ株式会社 | 超音波診断装置 |
| US9576357B2 (en) | 2013-01-17 | 2017-02-21 | Koninklijke Philips N.V. | Eliminating motion effects in medical images caused by physiological function |
| KR20140105103A (ko) | 2013-02-21 | 2014-09-01 | 삼성전자주식회사 | 장기의 움직임을 추적하는 방법, 장치 및 의료 영상 시스템 |
| CN103584847B (zh) | 2013-11-06 | 2015-04-22 | 中国人民解放军第三军医大学 | 一种非接触磁感应心率和呼吸率同步检测方法及系统 |
| JP2015159934A (ja) | 2014-02-27 | 2015-09-07 | セイコーエプソン株式会社 | 超音波計測装置及び超音波計測方法 |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| CN103948401A (zh) | 2014-05-20 | 2014-07-30 | 夏云 | 一种便携式肺功能仪器及肺功能检测方法 |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| JP2017527560A (ja) | 2014-09-03 | 2017-09-21 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 安定抗ｉｌ−４ｒアルファ抗体配合物 |
| CN107108745B (zh) | 2014-11-19 | 2021-01-12 | 基因泰克公司 | 抗bace1的抗体和其用于神经疾病免疫疗法的用途 |
| US9382321B2 (en) | 2014-11-26 | 2016-07-05 | Adventis Health System/Sunbelt, Inc. | Effector-deficient anti-CD32A antibodies |
| TWI701258B (zh) | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| CA2973964A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| CN104840218B (zh) | 2015-06-09 | 2018-08-10 | 联想(北京)有限公司 | 一种呼吸速率的测量方法及电子设备 |
| EP4435105A2 (en) | 2015-09-29 | 2024-09-25 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| CN109069622A (zh) | 2015-09-30 | 2018-12-21 | 詹森生物科技公司 | 特异性结合人cd40的拮抗性抗体和使用方法 |
| GB201519985D0 (en) | 2015-11-12 | 2015-12-30 | Respinor As | Ultrasonic method and apparatus for respiration monitoring |
| CN108367555B (zh) | 2015-12-18 | 2023-06-13 | 陶氏环球技术有限责任公司 | 适用于热成型应用的多层膜 |
| JP7064666B2 (ja) | 2016-04-29 | 2022-05-11 | ヴィエラ バイオ，インコーポレーテッド | ＦｃγＲＩＩＡに特異的な結合分子及びその使用 |
| MX2019008197A (es) | 2017-01-06 | 2019-09-11 | Scholar Rock Inc | Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos. |
| TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2020061159A1 (en) | 2018-09-20 | 2020-03-26 | Vanderbilt University | Human antibodies to zika virus |
| JP2023512684A (ja) * | 2020-02-03 | 2023-03-28 | ヴィア・バイオテクノロジー・インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法 |
| JP2023519105A (ja) | 2020-02-11 | 2023-05-10 | ヴァンダービルト ユニバーシティ | 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）に対するヒトモノクローナル抗体 |
| BR112022017048A2 (pt) | 2020-02-26 | 2022-11-16 | Vir Biotechnology Inc | Anticorpos contra sars-cov-2 e métodos para usar os mesmos |
| WO2021183195A1 (en) | 2020-03-09 | 2021-09-16 | 1.Abcellera Biologics Inc. | Anti-coronavirus antibodies and methods of use |
| US11053304B1 (en) * | 2020-03-23 | 2021-07-06 | Centivax, Inc. | Anti-SARS-Cov-2 antibodies derived from 6nb6 |
| AU2021242306A1 (en) | 2020-03-26 | 2022-11-17 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| JP7116256B1 (ja) | 2020-04-02 | 2022-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片 |
| WO2021203053A1 (en) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
| EP3921034A2 (en) | 2020-04-28 | 2021-12-15 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies and methods of use thereof |
| WO2021226560A1 (en) | 2020-05-08 | 2021-11-11 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 |
| WO2021231237A2 (en) | 2020-05-11 | 2021-11-18 | Augmenta Bioworks, Inc. | Antibodies for sars-cov-2 and uses thereof |
| WO2021229540A2 (en) | 2020-05-15 | 2021-11-18 | Universidad Austral De Chile | Single domain vhh antibodies against sars-cov-2 virus |
| PE20231376A1 (es) | 2020-05-17 | 2023-09-07 | Astrazeneca Uk Ltd | Anticuerpos contra el sars-cov-2 y metodos e seleccion y uso de los mismos |
| MX2022014420A (es) | 2020-05-20 | 2023-03-21 | Univ Columbia | Potentes anticuerpos neutralizantes contra el sars-cov-2, generacion y usos de los mismos. |
| EP4161960A1 (en) | 2020-06-03 | 2023-04-12 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
| EP4188951A4 (en) | 2020-07-27 | 2024-08-28 | IGM Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| BR112023002234A2 (pt) | 2020-08-10 | 2023-03-07 | Astrazeneca Uk Ltd | Anticorpos sars-cov-2 para tratamento e prevenção de covid-19 |
| WO2022035197A1 (ko) | 2020-08-11 | 2022-02-17 | (주)셀트리온 | 안정한 약제학적 제제 |
| JP2024509055A (ja) | 2021-02-04 | 2024-02-29 | アールキュー・バイオテクノロジー・リミテッド | 抗体 |
| US20240117011A1 (en) | 2021-02-09 | 2024-04-11 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Antibodies targeting the spike protein of coronaviruses |
| KR20230156737A (ko) | 2021-03-14 | 2023-11-14 | 아이코사겐 셀 팩토리 오위 | 소 초유 유래 항체 및 이의 용도 |
| TW202342095A (zh) | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | 用於治療和預防ｃｏｖｉｄ—１９之組成物 |
| WO2023084055A1 (en) | 2021-11-12 | 2023-05-19 | Rq Biotechnology Limited | Compositions |
| TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Ｒｑ生物科技有限公司 | 抗體 |
-
2021
- 2021-03-25 AU AU2021242306A patent/AU2021242306A1/en active Pending
- 2021-03-25 CA CA3175110A patent/CA3175110A1/en active Pending
- 2021-03-25 EP EP23209693.3A patent/EP4356924A3/en active Pending
- 2021-03-25 FI FIEP21719462.0T patent/FI4045533T3/fi active
- 2021-03-25 CN CN202180023056.7A patent/CN115768790A/zh active Pending
- 2021-03-25 ES ES21719462T patent/ES2973425T3/es active Active
- 2021-03-25 SI SI202130109T patent/SI4045533T1/sl unknown
- 2021-03-25 IL IL296537A patent/IL296537A/en unknown
- 2021-03-25 LT LTEPPCT/US2021/024215T patent/LT4045533T/lt unknown
- 2021-03-25 RS RS20240202A patent/RS65199B1/sr unknown
- 2021-03-25 HU HUE21719462A patent/HUE065039T2/hu unknown
- 2021-03-25 JP JP2022557735A patent/JP2023518849A/ja active Pending
- 2021-03-25 HR HRP20240182TT patent/HRP20240182T1/hr unknown
- 2021-03-25 WO PCT/US2021/024215 patent/WO2021195418A1/en active Application Filing
- 2021-03-25 PL PL21719462.0T patent/PL4045533T3/pl unknown
- 2021-03-25 TW TW110110951A patent/TW202200610A/zh unknown
- 2021-03-25 CR CR20220545A patent/CR20220545A/es unknown
- 2021-03-25 SM SM20240070T patent/SMT202400070T1/it unknown
- 2021-03-25 UY UY0001039135A patent/UY39135A/es unknown
- 2021-03-25 EP EP21719462.0A patent/EP4045533B1/en active Active
- 2021-03-25 US US17/212,949 patent/US11345741B2/en active Active
- 2021-03-25 DK DK21719462.0T patent/DK4045533T5/da active
- 2021-03-25 BR BR112022018949A patent/BR112022018949A2/pt unknown
- 2021-03-25 PH PH1/2022/552500A patent/PH12022552500A1/en unknown
- 2021-03-25 MX MX2022011892A patent/MX2022011892A/es unknown
- 2021-03-25 KR KR1020227036951A patent/KR20220158053A/ko active Search and Examination
- 2021-03-25 PT PT217194620T patent/PT4045533T/pt unknown
- 2021-03-25 PE PE2022002090A patent/PE20230415A1/es unknown
-
2022
- 2022-03-18 US US17/655,503 patent/US12216120B2/en active Active
- 2022-09-21 DO DO2022000199A patent/DOP2022000199A/es unknown
- 2022-09-23 CL CL2022002594A patent/CL2022002594A1/es unknown
- 2022-10-19 CO CONC2022/0014820A patent/CO2022014820A2/es unknown
- 2022-10-26 EC ECSENADI202283269A patent/ECSP22083269A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240182T1 (hr) | Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2) | |
| HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
| JP2024016177A5 (hr) | ||
| JP2020079252A5 (hr) | ||
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2020518600A5 (hr) | ||
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| JP2018535650A5 (hr) | ||
| IL259940B2 (en) | A method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists | |
| JP2015514110A5 (hr) | ||
| JP2017528476A5 (hr) | ||
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| RU2017104815A (ru) | Молекулы со специфичностью в отношении cd79 и cd22 | |
| JP2006512899A5 (hr) | ||
| JP2020509031A5 (hr) | ||
| JP2019504032A5 (hr) | ||
| JP2012504955A5 (hr) | ||
| PE20120554A1 (es) | Polipeptidos y metodo de tratamiento | |
| JPWO2021217004A5 (hr) | ||
| RU2017144629A (ru) | Тромбин-связывающие молекулы антител и их применение | |
| RU2014145536A (ru) | Антитело против adamts-5, его производные и их применение | |
| PE20221151A1 (es) | Anticuerpos anti-cd96 y sus metodos de uso | |
| PE20221865A1 (es) | Anticuerpos contra el virus de la fiebre amarilla y metodos de su generacion y uso |